Skip to main content
. 2014 Jun;55(6):1087–1097. doi: 10.1194/jlr.M045500

Fig. 2.

Fig. 2.

Implications of p62 on lipogenic pathways. Real-time RT-PCR (n = 3–6, triplicate) (A) or Western blot (n = 3, duplicate) (B) of HepG2 cells transfected with either p62 siRNA (si p62) or p62 overexpression vector (p62) and their respective controls (si co, co-v). A: MLXIPL, NR1H3, and SREBF1c mRNA. B: Precursor SREBF1 (SREBF1 pre) and mature SREBF1 (SREBF1 ma). C: SREBF1 pre and SREBF1 ma Western blot of wild-type (wt) and p62 transgenic (p62 tg) livers (n = 6). D: SREBF1 pre and SREBF1 ma Western blot on cytosolic and nuclear proteins of HepG2 cells treated with IGF2 (n = 9, duplicate). E: SREBF1 pre and SREBF1 ma and ELOVL6 Western blot on cytosolic and nuclear proteins of HepG2 cells (co) incubated with neutralizing IGF2 antibody (IGF2 AB, 48 h) (n = 4, duplicate). F: Real-time RT-PCR for ELOVL6 and p62 of 35 liver tissues normalized on ACTB mRNA levels.